Enhabit, Inc. (EHAB) Research

Enhabit, Inc. operates as a U.S.-based provider of home healthcare and hospice services. Its comprehensive home health division offers various services, such as patient education, pain management, wound care (including dressing changes), cardiac rehabilitation, infusion therapy, pharmaceutical administration, and expert observation and assessment. The company specializes in managing chronic conditions like diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care, and persistent pain. Additionally, Enhabit provides tailored disease-specific plans for individuals with diabetes, congestive heart failure, those recovering from orthopedic surgery or injuries, and patients with respiratory illnesses. Complementing these medical offerings, licensed physical, occupational, and speech therapists deliver vital rehabilitative support. Beyond home health, Enhabit delivers extensive hospice services designed to meet the physical, emotional, spiritual, and psychosocial needs of terminally ill patients and their families. These services encompass pain and symptom control, palliative and dietary counseling, social worker visits, spiritual guidance, and bereavement support. As of March 31, 2022, Enhabit maintained a significant operational footprint, with 252 home health agencies and 99 hospice agencies spread across 34 states. Established in 2014 and headquartered in Dallas, Texas, the company was previously known as Encompass Health Home Health Holdings, Inc., officially rebranding to Enhabit, Inc. in March 2022. Enhabit, Inc. began operating as a completely independent entity on July 1, 2022.

Open Enhabit, Inc. (EHAB) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.